AB0350 Rituximab Seems Outstanding Biological Option in Late Onset Rheumatoid Arthritis: Hur-Bio Real Life Results

BackgroundRheumatoid arthritis (RA) can be categorized into late-onset RA and young-onset RA. Age at disease onset may implicate on disease activity, disease severity, comorbidity and also may have an impact on physicians' treatment choices.ObjectivesThe aim of this study was to assess clinical and laboratory features, disease activity, response, and biological treatment choices according to late-onset RA and young-onset RA patients.MethodsHacettepe University Biologic Registry (HUR-BIO) is a single center biological registry since 2005. HUR-BIO biological dataset included demographic and clinical data and disease activity parameters. A total of 1087 (79.4% female) patients from the HURBIO registry were analyzed. Patients were categorized into two groups: young-onset RA (n=990, 0.05) was used similar in both group. Change in DAS-28 score was similar [1.55±1.14 vs. 1.79±1.45 (p>0.05)], in late-onset RA and young-onset RA patients. Remission (29.5% vs. 38.6%, p>0.05) and low disease activity (52.5% vs. 55.4%, p>0.05) were similar in late-onset RA and young-onset RA patients. Biological switch ratio was significantly lower in late-onset RA group, 18.6% vs. 35.2%, p